Stock Track | Edwards Lifesciences Soars 5.24% in Pre-market on Q1 Earnings Beat and Raised Annual Forecast

Stock Track04-24 20:40

Edwards Lifesciences' stock surged 5.24% in pre-market trading following the release of stronger-than-expected first-quarter financial results and an upward revision to its full-year outlook.

The medical device company reported quarterly sales and profit that exceeded analyst estimates, driven by robust demand for its artificial heart valves. Notably, sales of its transcatheter aortic valve replacement (TAVR) device rose 14.4% year-over-year to $1.2 billion, surpassing expectations.

Based on this performance, the company raised its annual adjusted profit forecast to a range of $2.95 to $3.05 per share, from a prior view of $2.90 to $3.05. It also increased its annual sales growth guidance to 9% to 11%, up from the previous range of 8% to 10%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1106891880?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-24 20:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106891880","market":"sg","top_or_hot":-1,"title":"Stock Track | Edwards Lifesciences Soars 5.24% in Pre-market on Q1 Earnings Beat and Raised Annual Forecast","media":"Stock Track","content":"<p>Edwards Lifesciences' stock surged 5.24% in pre-market trading following the release of stronger-than-expected first-quarter financial results and an upward revision to its full-year outlook.</p><p>The medical device company reported quarterly sales and profit that exceeded analyst estimates, driven by robust demand for its artificial heart valves. Notably, sales of its transcatheter aortic valve replacement (TAVR) device rose 14.4% year-over-year to $1.2 billion, surpassing expectations.</p><p>Based on this performance, the company raised its annual adjusted profit forecast to a range of $2.95 to $3.05 per share, from a prior view of $2.90 to $3.05. It also increased its annual sales growth guidance to 9% to 11%, up from the previous range of 8% to 10%.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Edwards Lifesciences Soars 5.24% in Pre-market on Q1 Earnings Beat and Raised Annual Forecast</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Edwards Lifesciences Soars 5.24% in Pre-market on Q1 Earnings Beat and Raised Annual Forecast\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-24 20:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Edwards Lifesciences' stock surged 5.24% in pre-market trading following the release of stronger-than-expected first-quarter financial results and an upward revision to its full-year outlook.</p><p>The medical device company reported quarterly sales and profit that exceeded analyst estimates, driven by robust demand for its artificial heart valves. Notably, sales of its transcatheter aortic valve replacement (TAVR) device rose 14.4% year-over-year to $1.2 billion, surpassing expectations.</p><p>Based on this performance, the company raised its annual adjusted profit forecast to a range of $2.95 to $3.05 per share, from a prior view of $2.90 to $3.05. It also increased its annual sales growth guidance to 9% to 11%, up from the previous range of 8% to 10%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EW","symbol_name":"爱德华兹","start_time":0,"source_url":"","article_id":"1106891880","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106891880","pubTimestamp":1777034454,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Edwards Lifesciences' stock surged 5.24% in pre-market trading following the release of stronger-than-expected first-quarter financial results and an upward revision to its full-year outlook.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EW":"爱德华兹"},"translate_title":"个股追踪|Edwards Lifesciences盘前大涨5.24%，Q1盈利超预期上调","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EW":1},"content_text":"Edwards Lifesciences' stock surged 5.24% in pre-market trading following the release of stronger-than-expected first-quarter financial results and an upward revision to its full-year outlook.The medical device company reported quarterly sales and profit that exceeded analyst estimates, driven by robust demand for its artificial heart valves. Notably, sales of its transcatheter aortic valve replacement (TAVR) device rose 14.4% year-over-year to $1.2 billion, surpassing expectations.Based on this performance, the company raised its annual adjusted profit forecast to a range of $2.95 to $3.05 per share, from a prior view of $2.90 to $3.05. It also increased its annual sales growth guidance to 9% to 11%, up from the previous range of 8% to 10%.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1106891880","isCrawlerRequest":true}